Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Lipid accumulation and dendritic cell dysfunction in cancer

(2010) Donna L Herber et al.   NATURE MEDICINE

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

(2009) C Alfaro et al.   BRITISH JOURNAL OF CANCER

Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

(2009) P. Verdijk et al.   CLINICAL CANCER RESEARCH

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The functional significance behind expressing two IL-8 receptor types on PMN

(2009) RoseMarie Stillie et al.   JOURNAL OF LEUKOCYTE BIOLOGY

TGF-β and kynurenines as the key to infectious tolerance

(2009) Maria L. Belladonna et al.   TRENDS IN MOLECULAR MEDICINE

The Interleukin-8 Pathway in Cancer

(2008) D. J.J. Waugh et al.   CLINICAL CANCER RESEARCH

Maximizing dendritic cell migration in cancer immunotherapy

(2008) Pauline Verdijk et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cancer Immunotherapy by Dendritic Cells

(2008) Cornelis J.M. Melief   IMMUNITY

The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment

(2008) Charlotte Rolny et al.   JOURNAL OF EXPERIMENTAL MEDICINE